The Relative Strength (RS) Rating for ResMed climbed into a higher percentile Tuesday, as it got a lift from 68 to 79.
IBD's proprietary RS Rating identifies market leadership by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.
Decades of market research shows that the best stocks tend to have an RS Rating of at least 80 as they launch their biggest climbs. See if ResMed can continue to show renewed price strength and clear that threshold.
When To Sell Stocks To Lock In Profits And Minimize Losses
ResMed is not currently offering a proper buying opportunity. See if the stock goes on to build a chart pattern that could launch a new move.
ResMed showed 29% EPS growth in the latest quarterly report. Sales rose 10%. The next quarterly results are expected on or around Apr. 24.
ResMed holds the No. 8 rank among its peers in the Medical-Products industry group. Boston Scientific, Pro-Dex and Axogen are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
